Lilly looks to take the top spot in Indian diabetes market

Global awareness project and marketing distribution partnership with Indian pharma companies on the stocks

Eli Lilly has lined up a slew of initiatives to position itself as the top player in the antidiabetes space in India. Along with two new products to be rolled out this year, a US$30m global awareness project and marketing distribution partnership with Indian pharma companies is also on the stocks.

Late last year, the Indian arm of the company announced a 5-year $30m commitment to fight the rising burden of non-communicable diseases (NCD) in developing nations. Called the Lilly NCD Partnership, it will focus on creating awareness about diabetes in India and three other countries.

Companies